List of Excipients in Branded Drug BENZHYDROCODONE AND ACETAMINOPHEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
KVK-Tech Inc	BENZHYDROCODONE AND ACETAMINOPHEN	benzhydrocodone and acetaminophen	10702-345	CELLULOSE, MICROCRYSTALLINE	2030-07-01
KVK-Tech Inc	BENZHYDROCODONE AND ACETAMINOPHEN	benzhydrocodone and acetaminophen	10702-345	CROSPOVIDONE	2030-07-01
KVK-Tech Inc	BENZHYDROCODONE AND ACETAMINOPHEN	benzhydrocodone and acetaminophen	10702-345	POVIDONE K30	2030-07-01

Benzhydrocodone and Acetaminophen Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Benzhydrocodone and acetaminophen, marketed as Apadaz, is an immediate-release Schedule II opioid tablet containing 6.12 mg of benzhydrocodone hydrochloride, equivalent to 6.12 mg of benzhydrocodone, and 325 mg of acetaminophen per tablet. Its commercial differentiation comes from benzhydrocodone, a prodrug converted in the body to hydrocodone, rather than from a complex delivery system. The formulation uses conventional tablet excipients, creating opportunities in supply security, lactose-free redesign, manufacturability, and lifecycle extensions. Commercial upside is constrained by competition from low-cost hydrocodone-acetaminophen generics, opioid prescribing controls, and the limited size of the branded product market.

What is Apadaz and how does benzhydrocodone differ from hydrocodone?

Apadaz was approved by the U.S. Food and Drug Administration on June 20, 2018, under NDA 208653. It is indicated for short-term management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate [1].

Benzhydrocodone is a prodrug of hydrocodone. The product is designed to deliver hydrocodone after enzymatic conversion. The approved product is not labeled by FDA as an abuse-deterrent formulation. Its prodrug design does not eliminate the risks of opioid misuse, addiction, respiratory depression, overdose, or acetaminophen-induced liver injury [1].

Attribute	Apadaz
Active ingredients	Benzhydrocodone hydrochloride and acetaminophen
Strength	6.12 mg/325 mg per tablet
Dosage form	Immediate-release oral tablet
FDA approval	June 20, 2018
NDA	208653
Sponsor at approval	KemPharm, Inc.
Controlled-substance schedule	Schedule II
Primary commercial partner	KVK-Tech
Typical clinical use	Short-term acute pain
Maximum acetaminophen concern	Hepatotoxicity from cumulative daily exposure

The 6.12 mg benzhydrocodone strength is intended to provide approximately the hydrocodone exposure associated with 6.67 mg of hydrocodone bitartrate, according to the product labeling and clinical pharmacology data [1].

What excipients are used in benzhydrocodone and acetaminophen tablets?

The approved Apadaz tablet uses a conventional immediate-release excipient platform. The U.S. prescribing information identifies lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, and magnesium stearate among the inactive ingredients [1].

Excipient	Formulation function	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Cost-effective but limits lactose-free positioning
Microcrystalline cellulose	Diluent, binder, and tablet-strength contributor	Supports direct compression and robust compaction
Croscarmellose sodium	Superdisintegrant	Helps maintain immediate release
Povidone	Binder and granulation aid	Controls tablet strength and processability
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow
Magnesium stearate	Lubricant	Reduces ejection force but requires controlled blending
Film-coating system	Appearance, swallowability, and product identification	Enables color and branding without changing release

The formulation is commercially attractive because it does not depend on a specialized osmotic system, multiparticulate technology, lipid matrix, or device. A generic or 505(b)(2) developer can focus on powder flow, compaction, disintegration, content uniformity, chemical stability, and bioequivalence.

Which excipient attributes matter most for formulation development?

The main technical risks are blend uniformity, acetaminophen loading, benzhydrocodone stability, tablet disintegration, and lubricant sensitivity.

Moisture and chemical stability

The formulation should be assessed for water activity, hydrolysis, and interaction between benzhydrocodone hydrochloride and excipient impurities. Lactose grade, povidone moisture content, and packaging permeability can affect long-term stability. A moisture-barrier bottle or high-barrier blister may provide a stronger stability profile than a low-cost bottle, particularly in hot and humid markets.

Excipient suppliers can differentiate through:

• Low-moisture lactose and microcrystalline cellulose grades.
• Low-peroxide povidone.
• Controlled-particle-size croscarmellose sodium.
• Low-heavy-metal and low-reactive impurity profiles.
• Excipient documentation supporting nitrosamine risk assessments.

Compression and content uniformity

Acetaminophen represents more than 98% of the labeled active mass. Benzhydrocodone is present at a much lower level, which makes segregation control important. Direct compression is feasible, but powder-density differences can create blend-uniformity risk. Roller compaction or wet granulation may improve handling, although each process adds development and validation costs.

A practical formulation strategy is to use a preblend containing benzhydrocodone with a portion of microcrystalline cellulose or lactose before full-batch blending. The process should control blend time because excessive magnesium stearate mixing can reduce tablet tensile strength and slow disintegration.

Immediate-release performance

Croscarmellose sodium provides a straightforward route to rapid tablet breakup. Development should evaluate:

• Disintegration time across compression-force ranges.
• Dissolution in standard aqueous media.
• Impact of magnesium stearate concentration.
• Sensitivity to tablet hardness.
• Performance after accelerated aging.
• Similarity to the reference product across pH conditions.

A formulation that materially changes the release profile could face a more difficult regulatory path and may lose the simplicity of an ANDA strategy.

What formulation patents protect benzhydrocodone and acetaminophen products?

Patent protection has historically focused on benzhydrocodone compositions, prodrug chemistry, manufacturing, and methods of use rather than on a complex excipient platform. The relevant patent position must be evaluated through current FDA Orange Book listings, issued patent records, terminal disclaimers, patent-term adjustment, and any litigation or settlement history.

The principal legal questions for a competitor are:

1. Whether the reference product has active Orange Book-listed patents.
2. Whether an ANDA applicant must submit a Paragraph IV certification.
3. Whether the proposed formulation practices claims directed to benzhydrocodone compositions or manufacturing methods.
4. Whether an excipient substitution avoids the relevant claims.
5. Whether a 30-month stay or litigation affects approval timing.

An excipient change does not automatically avoid patent infringement. Claims can cover the active pharmaceutical ingredient, dosage form, concentration ranges, particle properties, manufacturing steps, or use of the product in pain treatment. A non-infringement analysis must be claim-specific.

What is the Orange Book status of Apadaz?

Apadaz is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The Orange Book determines whether a reference-listed drug has patents or regulatory exclusivity relevant to an ANDA applicant [2].

The product’s original five-year new chemical entity exclusivity period ran from the June 2018 approval date and therefore expired in 2023, subject to FDA’s regulatory treatment of the active moiety and any separate exclusivity periods. Current market entry depends more heavily on patent listings, ANDA review, controlled-substance requirements, and commercial economics than on NCE exclusivity.

FDA approval does not itself establish that a product is free of patent barriers. A launch assessment should separate:

Issue	Commercial effect
NCE exclusivity	Delayed ANDA submission during the protected period
Listed patents	May require Paragraph IV or other certification
Patent litigation	Can delay approval or launch
Controlled-substance status	Adds DEA compliance and quota considerations
Acetaminophen safety	Limits dosing and broadens labeling obligations
Reference-product bioequivalence	Determines ANDA development burden

When does Apadaz lose exclusivity and when can generic entry occur?

Apadaz lost its five-year NCE exclusivity period in 2023. Generic entry is not determined by that date alone. An ANDA applicant may need to address active patents and satisfy FDA bioequivalence requirements.

A generic launch could follow several paths:

• Launch after all relevant patents expire.
• Paragraph IV launch before patent expiry if the applicant prevails in litigation or reaches a settlement.
• At-risk launch if the applicant accepts potential infringement exposure.
• Authorized-generic or licensed launch through the product owner.
• 505(b)(2) development for a materially different dosage form, strength, or clinical use.

For a conventional immediate-release tablet, the lowest-cost pathway is generally an ANDA if the applicant can demonstrate pharmaceutical equivalence and bioequivalence. A 505(b)(2) strategy may have greater commercial value where the developer offers a new dosage form, a clinically meaningful excipient change, a pediatric presentation, or an alternative packaging and dosing configuration.

Which companies are challenging Apadaz, and what is the litigation status?

Public FDA approval materials do not establish a complete litigation or Paragraph IV record. The relevant data source for active patent challenges is the FDA Orange Book together with federal court dockets and ANDA litigation filings.

No commercial conclusion should be based solely on the absence of a prominently reported lawsuit. Small opioid products can have limited public litigation activity even when patent certifications are filed. A current diligence review should track:

• ANDA applicants identifying Apadaz as the reference product.
• Paragraph IV notices served on the patent owner.
• District court complaints under the Hatch-Waxman Act.
• Settlement terms and any agreed launch date.
• Whether a settlement includes an authorized-generic commitment.
• Whether patents are delisted, expired, or subject to terminal disclaimers.

The absence of a known public settlement does not create a guaranteed open launch date.

What excipient strategies create the strongest commercial opportunity?

The highest-value opportunities are incremental rather than transformational.

Lactose-free or low-allergen positioning

Replacing lactose with mannitol, anhydrous dibasic calcium phosphate, spray-dried cellulose, or a co-processed excipient could create a differentiated formulation. The commercial benefit would be modest because lactose intolerance is not generally a major barrier to oral tablet use, but lactose-free positioning can improve institutional formulary acceptance and manufacturing flexibility.

The replacement must preserve:

• Tablet hardness.
• Disintegration.
• Dissolution.
• Chemical stability.
• Content uniformity.
• Bioequivalence.

Direct-compression platform

A co-processed microcrystalline cellulose-based system could reduce granulation steps and improve manufacturing throughput. This opportunity is strongest for contract manufacturers and generic developers seeking fewer unit operations, lower solvent use, and shorter batch cycle times.

Moisture-protective packaging

Packaging is a practical lifecycle opportunity. High-barrier blister packaging, desiccant-containing bottles, and unit-dose hospital packaging can support stability and controlled dispensing. Unit-dose packaging also helps reduce medication errors involving hydrocodone-acetaminophen products.

Pediatric and geriatric presentations

A lower-strength tablet, orally disintegrating tablet, or sprinkle-compatible dosage form could support differentiated development. These products would likely require a 505(b)(2) pathway or separate clinical and bioequivalence work, depending on the formulation and labeling changes.

Manufacturing and supply-chain services

Excipient suppliers can capture value through qualified second sources, regulatory support, compendial documentation, and validated supply continuity. For a controlled opioid, manufacturers also need DEA registration, inventory controls, secure storage, reconciliation procedures, and quota planning.

How does Apadaz compare with hydrocodone-acetaminophen generics?

Factor	Apadaz	Generic hydrocodone-acetaminophen
Active opioid	Benzhydrocodone, converted to hydrocodone	Hydrocodone salt
Development basis	Branded NDA or 505(b)(2)	ANDA
Excipient differentiation	Possible through lifecycle products	Usually limited by reference-product equivalence
Price position	Branded or specialty product	Low-cost generic
Abuse-deterrent labeling	Not designated by FDA as abuse-deterrent	Typically not abuse-deterrent
Prescriber familiarity	Lower	High
Formulation complexity	Conventional immediate-release tablet	Conventional immediate-release tablet
Commercial barrier	Opioid controls and limited differentiation	Price compression and commoditization

Apadaz has a pharmacologic and intellectual-property distinction, but its tablet technology does not create a large manufacturing barrier. A competitor with a reliable, low-cost, bioequivalent product could place substantial pressure on price.

What FDA and regulatory barriers affect commercial development?

FDA review will focus on bioequivalence, quality, stability, manufacturing controls, labeling, and controlled-substance compliance. The product also carries opioid-class warnings and acetaminophen safety restrictions [1].

Key regulatory requirements include:

• ANDA or 505(b)(2) filing strategy.
• Pharmaceutical equivalence to the reference product.
• In vitro dissolution and, where required, pharmacokinetic bioequivalence.
• Stability data under ICH conditions.
• Control of degradation products and impurities.
• Opioid analgesic REMS obligations where applicable.
• DEA registration and Schedule II controls.
• Postmarketing pharmacovigilance.
• Labeling that prevents cumulative acetaminophen overdosing.

A reformulation that changes inactive ingredients may still require comparative bioavailability work, especially if the change affects dissolution or absorption.

What is the revenue exposure and competitive outlook?

Apadaz revenue exposure is likely smaller than that of established hydrocodone-acetaminophen products because the market is dominated by inexpensive generics and constrained opioid prescribing. Public sources do not provide a consistently reported, standalone Apadaz revenue series. The relevant commercial opportunity is therefore better assessed through prescription volume, payer coverage, wholesaler stocking, and net price rather than headline market size.

The product may retain value in three segments:

1. Patients or prescribers seeking a branded benzhydrocodone product.
2. Institutional buyers requiring dependable supply and unit-dose packaging.
3. Licensees developing differentiated dosage forms or regional products.

The core tablet is unlikely to sustain premium pricing without a clear clinical, safety, adherence, or supply-chain advantage.

Key Takeaways

• Apadaz is an immediate-release 6.12 mg/325 mg benzhydrocodone-acetaminophen tablet approved in 2018.
• Its excipient system is conventional and includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, and magnesium stearate.
• The strongest excipient opportunities are lactose-free redesign, direct compression, moisture control, unit-dose packaging, and qualified second sourcing.
• NCE exclusivity expired in 2023; patent listings and Paragraph IV activity remain central to generic-entry timing.
• The product is not FDA-designated as abuse-deterrent.
• Generic competition is the principal commercial threat because hydrocodone-acetaminophen is widely available at low cost.
• The most defensible commercial opportunities are differentiated dosage forms, manufacturing efficiency, supply reliability, and controlled-distribution packaging.

FAQs

Is benzhydrocodone the same as hydrocodone?

No. Benzhydrocodone is a prodrug that is converted to hydrocodone after administration. Apadaz therefore contains benzhydrocodone hydrochloride rather than hydrocodone bitartrate.

Can lactose be removed from an Apadaz-equivalent formulation?

Yes, lactose can potentially be replaced, but the developer must demonstrate acceptable stability, dissolution, disintegration, content uniformity, and bioequivalence. The change may affect the regulatory pathway.

Is Apadaz an abuse-deterrent opioid?

No. FDA approved Apadaz without labeling it as an abuse-deterrent formulation. The prodrug design does not eliminate opioid misuse or overdose risk.

Would a generic Apadaz require a Paragraph IV certification?

It may, depending on active Orange Book-listed patents at the time of ANDA submission. The certification requirement is determined by the current patent listing, not by the product’s original NCE exclusivity period.

Which excipient has the greatest commercial value in an Apadaz generic?

No single excipient is likely to create a durable premium. Co-processed direct-compression systems, low-moisture grades, low-peroxide povidone, and high-barrier packaging have the clearest practical value because they can improve manufacturing reliability and stability.

References

1. U.S. Food and Drug Administration. (2018). Apadaz (benzhydrocodone hydrochloride and acetaminophen) tablets: Prescribing information. NDA 208653.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2019). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. https://www.fda.gov/

4. U.S. Drug Enforcement Administration. (n.d.). Controlled substances schedules. https://www.dea.gov/drug-information/drug-scheduling

5. KemPharm, Inc. (2018). KemPharm announces FDA approval of Apadaz. Company announcement.

6. U.S. Food and Drug Administration. (2020). Approved drug products with therapeutic equivalence evaluations, 40th edition. FDA.